Singapore, Jan. 5 -- Hong Kong headquartered Insilico Medicine, a leading artificial intelligence (AI)-driven drug discovery company, has announced a multi-year research and development (R&D) collaborationwith Servier, an independent international pharmaceutical company governed by a foundation.This strategic alliance is focused onidentifyingand developing novel therapeutics for challenging targets in theoncology spaceby leveraging Insilico's proprietary AI platform,Pharma.AI.

Under the agreement, Insilico will be eligible to receive up to $32million in upfront and near-term R&D payments and will lead the AI-driven discovery and development of potential drug candidates that meet predefined criteria, while Servier will share the R&D expen...